中国首例输入性中东呼吸综合征患者临床救治分析  

Clinical analysis of the first patient with imported Middle East respiratory syndrome in China

作　　者：凌云[1] 瞿嵘[1] 罗裕锋[1] 

机构地区：[1]广东省惠州市中心人民医院重症医学科,广东惠州516001

出　　处：《中华危重病急救医学》2015年第8期630-634,共5页Chinese Critical Care Medicine

摘　　要：目的：报告中国首例输入性中东呼吸综合征（MERS）患者的救治经过，探讨MERS的临床特点及治疗方案。方法2015年5月28日广东省惠州市中心人民医院重症医学科收治了中国首例输入性MERS患者，通过患者的临床资料及治疗经过，分析MERS的临床特点及治疗方案。结果输入性MERS患者男性，43岁，韩国人，因背部酸痛7 d、发热2 d入院。①病例特点：患者7 d前出现背部酸痛，无发热，无咳嗽、咳痰，被韩国疾病控制部门列为“中东呼吸综合征冠状病毒”（MERS-CoV）可疑感染者但未予特殊诊治；2 d前出现发热，体温最高达39.7℃，无畏寒、寒战，无咳嗽、咳痰，无气促，无腹痛、腹泻，无尿频、尿急，无咽痛；有明确MERS患者接触史，为韩国第二代人传人病例。②辅助检查：2015年5月29日中国疾病预防控制中心（中国CDC）对3份咽拭子标本进行病毒核酸检测显示均呈阳性，血清、痰液、粪标本也呈阳性。通过全基因组序列扩增与测定序列分析结果推测该病毒株可能来自沙特阿拉伯的Jeddah和Riyahh地区。入院时患者血液检查提示：白细胞偏低（3.22x109/L），中性粒细胞比例偏高（0.73），血小板偏低（81x109/L）。入院时患者床旁X线胸片提示：双下肺少量渗出性病灶。③治疗措施：给予呼吸湿化吸氧仪加强氧疗（吸入氧浓度0.50～0.80，可耐受时设定流量为60 L/min），入院第20天改为鼻导管低流量吸氧，第24天停用；利巴韦林2.0 g口服负荷剂量后改为600 mg、8 h 1次（q8h），入院第10天减为600 mg、12 h 1次（q12h），第13天停用；入院第4天加用头孢曲松钠2.0 g、每日1次（qd）抗感染，第7天改为美罗培南2.0 g、q8h，2周后停用；静脉注射人免疫球蛋白20 g、qd，共用7 d，入院第8天加用胸腺肽α1治疗，2周后停用；干扰素每周1次（仅用1次）；同时给予护肝及继续口服甲硫咪唑ObjectiveTo report the treatment of the first imported Middle East respiratory syndrome （MERS） in China, and to investigate the clinical features and treatment of the patient.Methods On May 28th, 2015, the first patient of imported MERS to China was admitted to Department of Critical Care Medicine of Huizhou Municipal Central Hospital. The clinical features and treatments of this patient were analyzed.Results①A 43 years old male of South Korean nationality was admitted with the complaint of back ache for 7 days and fever 2 days with the following characteristics： back ache 7 days ago, without fever or cough or expectoration. He had been suspected to suffer from infection of Middle East respiratory syndrome coronavirus （MERS-CoV） by the Disease Control Department of South Korea, but no specific treatment was given. He had fever for 2 days with maximum body temperature of 39.7℃. He had no chills, cough, expectoration, short of breath, abdominal pain, diarrhea, frequent micturition, or urgency or pain of urination, and no sore throat. The patient had a history of exposure to MERS-CoV patient. He was considered to be a patient of the second batch of South Korean epidemic.② Auxiliary examination： 3 copies of throat swab specimens for virus nucleic acid detection were performed by the Disease Prevention Control Center of China （China CDC）, and they were positive on May 29th, 2015, and also for serum, sputum and stool. Based on the results of whole genome sequence analysis, the virus strains were implicated to be derived from Riyahh and Jeddah regions of Saudi Arabia. On admission, the patient＇s blood test showed that the white blood cell count was low （3.22x109/L）, the proportion of the neutrophils was high （0.73）, and that of the platelet was low （81x109/L）. On admission, the patient＇s chest X-ray showed that a small amount of infiltration in the lung.③ Treatment： a high-flow nasal cannula （HFNC） with oxygen concentration of 0.50-0.80 was given, with a flow rate was set at

关 键 词：中东呼吸综合征 冠状病毒 临床治疗 抗病毒药物 

分 类 号：R511[医药卫生—内科学]